FY2026 EPS beat and margin shift to specialty drive FY2027 growth outlook. Click to read more about the pros and cons of ...

Cardinal Health had a mixed fiscal fourth quarter in terms of sales across its two main business lines, but expects revenue ...

Cardinal Health reports mixed quarterly performance across its business segments as earnings get a lift from one-time tariff ...

Cardinal Health Inc. (NYSE:CAH) shares advanced in pre-market trading on Tuesday after the healthcare company delivered ...

Cardinal Health (NYSE:CAH) reported fourth-quarter fiscal 2026 results marked by growth in revenue, operating earnings and adjusted earnings per share, supported by demand in its pharmaceutical and ...

Cardinal Health today released Q4 results that handily beat the Wall Street consensus on profits, even as it missed on revenue.

Cardinal Health Inc. (NYSE:CAH) on Thursday reported third-quarter 2025 adjusted EPS of $2.35, up 13% year over year, beating the consensus of $2.17. Sales remained flat at $54.9 billion, missing the ...

Cardinal Health (NYSE:CAH) reports today. Explore the key operating questions around pharmaceutical distribution and specialty care, business execution, demand quality, and financial flexibility.

CFO Alt guided fiscal 2027 EPS to “between $12.40 and $12.60,” and said the company is “reconfirming our long-term EPS growth rate guidance of 12% to 14% per year,” while guiding “EPS growth of 13% to ...

Cardinal Health, which manufactures and distributes medical and laboratory products, has entered into a definitive agreement to acquire Integrated Oncology Network, a physician-led independent ...